REV-ERB agonist is one of those subjects where the details matter more than the headlines. This page pulls together the background, the mechanisms, and the practical points readers ask about most.
Updated 2026-04-11. Numbers and descriptions here follow the published literature rather than marketing material.
SR9009 is a synthetic small molecule studied as an agonist of the nuclear receptors REV-ERBα and REV-ERBβ. These receptors help regulate circadian rhythms, lipid metabolism, and inflammatory gene expression. In cell and animal experiments, SR9009 alters transcription of clock-controlled genes and metabolic pathways. The compound is not a hormone and does not resemble classical steroid structures. Its activity depends on binding to the ligand-binding domain of REV-ERB, where it can modify corepressor recruitment.
Research interest in SR9009 grew from studies of circadian biology and metabolic disease. Preclinical reports describe effects on exercise capacity, muscle metabolism, and blood lipid levels in rodents, but these findings come from controlled laboratory settings. The compound has low oral bioavailability in animals, which limits systemic exposure after swallowing. Investigators often use injected routes in experiments to achieve measurable plasma concentrations. Human clinical data are sparse, no approved therapeutic product exists, and whether animal effects translate to humans remains an open question.
Regulatory and sporting contexts treat SR9009 as a prohibited substance in many elite competitions. Its presence on banned lists reflects concerns about performance enhancement and unknown long-term safety. Analytical chemists have developed methods to detect the parent compound and its metabolites in urine and blood. Literature discussions distinguish between in vitro potency, animal pharmacology, and anecdotal human reports. The latter are difficult to verify because products sold online may lack purity or contain different compounds.
In rodent studies, SR9009 has been reported to increase mitochondrial content in skeletal muscle and improve exercise endurance under some conditions. These findings led to popular descriptions such as an exercise mimetic, although that term oversimplifies the biology. Effects vary by dose, timing, tissue, and model. The compound's influence on circadian pathways means that time of administration can matter in experiments. Whether similar metabolic changes occur in humans remains largely unexplored in controlled published trials.
Pharmacokinetic data for SR9009 are limited in published literature. Some reports indicate low oral bioavailability and rapid clearance in animals, which complicates interpretation of exposure and effect. Researchers often use injected routes in preclinical work to achieve measurable systemic levels. Analytical studies rely on mass spectrometry to detect the parent compound and its metabolites. Questions about tissue distribution, active metabolites, and long-term consequences remain open. Species differences in metabolism can affect observed half-life and target engagement.
SR9009 is a synthetic small molecule studied as an agonist of the nuclear receptors REV-ERBα and REV-ERBβ. These receptors help regulate circadian rhythms and metabolic gene expression. In laboratory experiments, SR9009 binds these receptors and alters transcription of genes involved in lipid handling, glucose metabolism, and mitochondrial function. It is not a naturally occurring compound and has no approved therapeutic use. Research interest stems from its ability to modify energy metabolism in cells and animal models.
| Property | Value | Notes |
|---|---|---|
| Chemical class | Synthetic REV-ERB agonist | Binds REV-ERBα and REV-ERBβ in preclinical models |
| Molecular formula | C20H24ClN3O4S | Reported for the parent compound |
| CAS Registry Number | 1379686-30-2 | Common identifier in chemical databases |
| Appearance | Off-white to pale yellow solid | Typical research chemical solid |
| Solubility | Soluble in DMSO and ethanol; low in water | Class: small organic molecule |
Laboratory studies often administer SR9009 by injection because oral absorption appears poor in rodents. Reported pharmacokinetic properties include rapid metabolism and low systemic exposure after oral dosing. Human pharmacokinetic data are sparse, so absorption, distribution, metabolism, and excretion in people are not well defined. Some research explores related REV-ERB compounds with improved drug-like properties. Regulatory approval for any REV-ERB agonist as a human medicine has not been granted to date.
SR9009 is a synthetic small molecule studied as an agonist of the nuclear receptors REV-ERBα and REV-ERBβ, also called NR1D1 and NR1D2. These receptors help regulate circadian rhythms and metabolic gene programs. The compound was developed for laboratory research, not as an approved therapeutic. Its identity is distinct from steroid hormones and selective androgen receptor modulators. Scientific interest centers on how REV-ERB activation changes gene expression in cells and animal models.
At the molecular level, SR9009 binds the ligand-binding domain of REV-ERB and strengthens recruitment of corepressor proteins such as NCoR and HDAC3. This increases repression of target genes, including Bmal1 and other clock-controlled and metabolic genes. In rodent studies, such changes have been linked to altered lipid handling, glucose metabolism, and energy expenditure. The precise chain of events between receptor binding and whole-body effects remains an active area of research. Findings in animals do not automatically translate to humans.
Mechanistically, SR9009 binds the ligand-binding domain of REV-ERBα/β and enhances recruitment of corepressor complexes. This represses target genes rather than activating them. Because REV-ERB proteins normally compete with ROR proteins at shared response elements, the net effect depends on tissue and timing. Researchers use SR9009 to probe how nuclear receptor signaling links the clock to metabolism, inflammation, and muscle biology. Findings are largely preclinical, and the precise contribution of each receptor subtype remains under study.
SR9009 is frequently discussed in fitness and research-chemical contexts, yet it has no approved medical indication. Regulatory agencies have not authorized it for human use, and it is not a standard prescription drug. Some sports organizations list it as a prohibited substance because of its potential performance-enhancing properties. Published human data are sparse, so claims about its effects in people often rely on animal models or anecdotal reports. Quality and identity of online materials can vary widely.
== Analogue controls == Several jurisdictions have implemented analogue law controls of fentanyl analogues in an attempt to pre-emptively ban novel derivatives before they appear on the market. One representative example is the New Zealand provisions enacted in 1988 in response to the first wave of fentanyl derivatives. This bans a set of structures as follows; "Fentanyl analogues, in which the N-[1-(2-phenethyl)-4-piperidyl]aniline nucleus has additional radicals, either alone or in combination, attached as follows: (a) an acetyl, propionyl, butenoyl or butanoyl radical, attached to the aniline nitrogen atom: (b) 1 or more alkyl radicals, with up to 10 carbon atoms in total, attached to the ethyl moiety: (c) any combination of up to 5 alkyl radicals and/or alkoxy radicals (each with up to 6 carbon atoms, including cyclic radicals) and/or halogen radicals, attached to each of the benzene rings." A more recent and somewhat broader example was introduced into US Federal legislation in 2018, covering the following structures; "...fentanyl-related substances includes any substance not otherwise controlled in any schedule...that is structurally related to fentanyl by one or more of the following modifications:
fixation 1. (histology) The preservation of biological material by treating it with a chemical fixative that prevents or delays the natural postmortem processes of decay (e.g. autolysis and putrefaction) which would otherwise eventually cause cells, tissues, and biomolecules to lose their characteristic structures and properties. Biological specimens are usually fixed with the broad objective of arresting or slowing biochemical reactions for long enough to study them in detail, essentially 'freezing' cellular processes in their natural state at a specific point in time, while minimizing disruption to existing structures and arrangements, all of which can improve subsequent staining and microscopy of the fixed samples. Though fixation tends to irreversibly terminate any ongoing reactions, thus killing the fixed cells, it makes it possible to study molecular details that occur too rapidly or transiently to observe in living samples. Common fixatives such as formaldehyde work by disabling proteolytic enzymes, coagulating, insolubilizing, and/or denaturing macromolecules, creating crosslinks between them, and protecting specimens from decomposition by bacteria and fungi. 2. (population genetics) The process by which a single allele for a particular gene with multiple different alleles increases in frequency in a given population such that it becomes permanently established as the only allele at that locus within the population's gene pool.
In a DNA double helix, each type of nucleobase on one strand bonds with just one type of nucleobase on the other strand. This is called complementary base pairing. Purines form hydrogen bonds to pyrimidines, with adenine bonding only to thymine in two hydrogen bonds, and cytosine bonding only to guanine in three hydrogen bonds. This arrangement of two nucleotides binding together across the double helix (from six-carbon ring to six-carbon ring) is called a Watson-Crick base pair. DNA with high GC-content is more stable than DNA with low GC-content. A Hoogsteen base pair (hydrogen bonding the 6-carbon ring to the 5-carbon ring) is a rare variation of base-pairing. As hydrogen bonds are not covalent, they can be broken and rejoined relatively easily. The two strands of DNA in a double helix can thus be pulled apart like a zipper, either by a mechanical force or high temperature. As a result of this base pair complementarity, all the information in the double-stranded sequence of a DNA helix is duplicated on each strand, which is vital in DNA replication. This reversible and specific interaction between complementary base pairs is critical for all the functions of DNA in organisms.
Biotechnology is a rapidly evolving field with significant potential to address pressing global challenges and improve the quality of life for people around the world; however, despite its numerous benefits, it also poses ethical and societal challenges, such as questions around genetic modification and intellectual property rights. As a result, there is ongoing debate and regulation surrounding the use and application of biotechnology in various industries and fields.
Sources: en.wikipedia.org
== Clinical studies == Randomized trials have evaluated Dexcom systems as part of real-time CGM-based diabetes management. In the 2020 MILLENNIALS crossover trial, participants aged 16–24 years with type 1 diabetes used the Dexcom G6 for eight weeks and conventional self-monitoring of blood glucose for eight weeks. During G6 use, the mean percentage of time in the target glucose range of 70–180 mg/dL was 35.7%, compared with 24.6% during self-monitoring, and mean glycated hemoglobin (HbA1c) was 0.76 percentage points lower. The 2021 MOBILE trial randomly assigned 175 adults with poorly controlled type 2 diabetes, treated with basal insulin but not mealtime insulin, to use either the G6 or a conventional blood glucose meter for eight months. HbA1c decreased by 1.1 percentage points in the G6 group and by 0.6 points in the meter group; after adjustment, the between-group difference was 0.4 percentage points. Mean time in the 70–180 mg/dL range was 59% with the G6 and 43% with meter monitoring, while one participant in each group experienced severe hypoglycemia. The study and devices were funded by Dexcom, and a Dexcom employee was among the authors. Both trials compared a CGM-enabled management strategy with fingerstick-based monitoring; they did not compare the G6 with another CGM system.
In fact, actin is capable of acting as a transcription initiator when it reacts with a type of nuclear myosin that interacts with RNA polymerases and other enzymes involved in the transcription process. Stereocilia dynamics. Some cells develop fine filiform outgrowths on their surface that have a mechanosensory function. For example, this type of organelle is present in the Organ of Corti, which is located in the ear. The main characteristic of these structures is that their length can be modified. The molecular architecture of the stereocilia includes a paracrystalline actin core in dynamic equilibrium with the monomers present in the adjacent cytosol. Type VI and VIIa myosins are present throughout this core, while myosin XVa is present in its extremities in quantities that are proportional to the length of the stereocilia. Intrinsic chirality. Actomyosin networks have been implicated in generating an intrinsic chirality in individual cells. Cells grown out on chiral surfaces can show a directional left/right bias that is actomyosin dependent.
Antipyrine-benzocaine otic consists of antipyrine and benzocaine, and is used to relieve ear pain and remove earwax. Cepacol consists of menthol and benzocaine, and is used to treat sore throat. A solution of benzocaine and menthol is marketed for the treatment of bee stings, mosquito bites, jellyfish stings, and other insect bites
=== 1973 === January 27: The Paris Peace Accords end American involvement in the Vietnam War. Congress cuts off funds for the continued bombing of Indochina. February: Balochi separatists launched a five-year long guerilla war against the Pakistani government in order to create a separate Balochistan nation. February 21: Vientiane Treaty is signed as a cease-fire agreement for the Laotian Civil War. The treaty calls for the removal of all foreign soldiers from Laos . The treaty calls for a coalition government to be created but never materialized. July 10: The Bahamas becomes independent from the UK. July 29: To help further legitimize their rule, the Greek Junta abolished the Greek monarchy after a sham referendum. September: West Germany and East Germany are each admitted to the United Nations. September 11: Chilean coup d'état — The democratically elected Marxist president of Chile, Salvador Allende, is deposed and dies of a gunshot wound during a military coup led by General Augusto Pinochet. October 6: Yom Kippur War — Israel is attacked by Egypt and Syria, the war ends with a ceasefire. October 14: An uprising occurred in Thailand. October 22: Egypt defects to the American camp by accepting a U.S. cease-fire proposal during the October 1973 war. November 11: The Soviet Union announces that, because of its opposition to the recent overthrow of the government of Chilean President Salvador Allende, it will not play a World Cup Soccer match against the Chilean team if the match is held in Santiago.
Calcium carbonate is a chemical compound with the chemical formula CaCO3. It is a common substance found in rocks as the minerals calcite and aragonite, most notably in chalk and limestone, eggshells, gastropod shells, shellfish skeletons and pearls. Materials containing much calcium carbonate or resembling it are described as calcareous. Naturally occurring calcium carbonate is important part of the carbon cycle, sequestering large amounts of carbon in geological formations. When acidic rain or water enters a natural deposit of calcium carbonate, it can lead to cave formation with stalactite and stalagmite. Calcium carbonate is the active ingredient in agricultural lime, an important ingredient for correcting soil chemistry. Limescale is calcium carbonate produced when calcium ions in hard water react with carbonate ions. Calcium carbonate has medical use as a calcium supplement or as an antacid, but excessive consumption can be hazardous and cause hypercalcemia and digestive issues. Other major uses include as a ingredient in construction materials, an ingredient in smelting iron and as a filler in paper or plastic.
Sources: en.wikipedia.org
SR9009 is a synthetic small molecule studied as an agonist of the REV-ERB nuclear receptors. It is not an approved medicine, and its effects in humans are not well characterized.
No. It is a synthetic ligand that binds nuclear receptors, not a steroid or peptide hormone. Its activity depends on receptor binding rather than endocrine secretion.
Clinical evidence is limited. Most published data come from cell and animal experiments. Human safety and efficacy remain uncertain.
It is a synthetic research compound that activates REV-ERB nuclear receptors. It is not an approved drug or dietary supplement. Most information comes from cell and animal studies.